Related Experiment Videos
Methylphenidate effects in attention deficit/hyperactivity disorder: electrodermal and ERP measures during a
Carlie A Lawrence1, Robert J Barry, Adam R Clarke
1Department of Psychology and Brain & Behaviour Research Institute, University of Wollongong, Wollongong 2522, Australia.
Psychopharmacology
|September 15, 2005
Summary
Methylphenidate (MPH) improved attention deficit/hyperactivity disorder (AD/HD) symptoms in children, normalizing behavioral and brain activity measures. This supports a hypo-arousal model for AD/HD, explaining MPH
Area of Science:
- Neuroscience
- Child Psychology
- Psychopharmacology
Background:
- Limited research on stimulant effects in ADHD using autonomic measures.
- Methylphenidate (MPH) is a common stimulant for ADHD.
- Autonomic arousal is a key area for ADHD research.
Purpose of the Study:
- To investigate MPH effects on central and autonomic measures in ADHD children.
- To utilize a continuous performance task (CPT) in an open-label study.
- To differentiate medication effects from retesting effects.
Main Methods:
- 36 boys (18 ADHD, 18 control) participated in a CPT.
- ADHD group received MPH 1 hour before the second trial.
- Measured performance (errors, RT), electrodermal activity, and event-related potentials (ERPs).
Main Results:
- ADHD children initially had more errors, which normalized post-medication.
- Skin conductance levels were lower in ADHD children, normalizing after MPH.
- ERP differences between groups diminished after medication.
Conclusions:
- MPH ameliorated behavioral and ERP dysfunctions in ADHD children.
- Electrodermal activity differences support a hypo-arousal model of ADHD.
- Findings explain MPH's mechanism of action in ADHD.